Angiogenesis-dependent diseases☆,☆☆
References (42)
- et al.
Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
Blood
(1993) - et al.
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion, parallel progression of human multiple myeloma
Blood
(1999) - et al.
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
Blood
(1999) - et al.
Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
Am J Pathol
(2000) - et al.
Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
Mol Ther
(2001) - et al.
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
Cell
(1994) - et al.
Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
Cell
(1997) - et al.
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Cancer Treat Rev
(2000) - et al.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Blood
(2000) - et al.
Thalidomide in the treatment of relapsed multiple myeloma
The von Hippel-Lindau tumor suppressor gene
Exp Cell Res
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
Ann Oncol
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
J Biol Chem
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
Blood
Tumor angiogenesis
Angiogenesis
Regulation of angiogenesis
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
J Natl Cancer Inst
Bone marrow angiogenesis and progression in multiple myeloma
Br J Haematol
Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
N Engl J Med
Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
Br J Cancer
Cited by (290)
The role of IL-1 in tumor growth and angiogenesis
2023, Multifaceted Role of IL-1 in Cancer and InflammationThe ER-mitochondria Ca<sup>2 +</sup> signaling in cancer progression: Fueling the monster
2021, International Review of Cell and Molecular BiologyCitation Excerpt :Later, in 1971 it was proposed that tumor growth and metastasis are angiogenesis dependent. Therefore, it was concluded that blocking angiogenesis could be a strategy to arrest tumor growth (Folkman, 2001). During tumor progression, angiogenesis is almost always activated and remains that way, causing normally quiescent vasculature to continually sprout new vessels that help sustain expanding neoplastic growth (Hanahan and Folkman, 1996).
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents
2020, Bioorganic ChemistryCitation Excerpt :Thalidomide was banned and withdrawn from the market, but many studies have continued to reveal the mechanism of its action [4–7]. Subsequently, thalidomide (1) has been shown to be efficacious in the treatment of different diseases, including cancer [8], acquired immunodeficiency syndrome (AIDS) [9], leprosy [9], multiple myeloma [10], and other angiogenesis-dependent disorders [11]. Thalidomide is considered as a prototype of the glutarimide-containing immunomodulatory agents [12].
Surface biofunctionalization of the decellularized porcine aortic valve with VEGF-loaded nanoparticles for accelerating endothelialization
2019, Materials Science and Engineering CITE Suppresses Angiogenic Responses in Human Artery and Vein Endothelial Cells: Differential Roles of AhR
2017, Reproductive Toxicology
- ☆
Update on “Angiogenesis-Dependent Diseases” presented at the Expert's Roundtable on Angiogenesis, Boston, MA, October 4, 2000.
- ☆☆
Supported in part by US Public Health Service Grant No. 2 P01 CA45548 from the National Cancer Institute, and by a grant to Children's Hospital from EntreMed Inc, Rockville, MD.